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Background: Chemotherapy (CT) induced cardiotoxicity is a potentially lethal
complication that frequently affects patients (pts) treated with anthracyclines and
targeted agents such as trastuzumab (Tr).
Patients and methods: From November 2013 to April 2015 we enrolled 30 patients;
median age 51 years (range 40-62) with HER2 positive breast cancer. All pts received
the same schedule of CT (17 in neoadiuvant and 13 in adiuvant setting): 4 cycles of EC
(Epirubicin 90 mg/mq ev q21, Cyclophosphamide 600 mg/mq ev q21), followed by
Paclitaxel 80 mg/mq ev q7 for 12 weeks and Tr 6 mg/Kg ev q21, (loading dose 8 mg/
Kg) given concomitantly up to a year of treatment. Echo-cardiogram with
two-dimensional and with three-dimensional approach were performed before starting
CT, after anthracyclines and then every 3 months after the start of Tr, up to one year of
completion. Several parameters of ventricular remodeling and function were evaluated:
two-dimensional EF ejection fraction (EF) (EF 2D), three-dimensional EF (EF 3D),
Global Longitudinal Strain (GLS), systolic s’ wave at TDI of the annulus (s’TDI),
Ventricular Elastance and Ventricular-Arterial Coupling.
Results: According to the latest data of the literature, 4 (13,3%) pts had a cardiac event
linked to the toxicity by EC and Tr: 2 pts had an important reduction of LVEF under
50% and 2 pts had an event of ACS (Acute Coronary Syndrome) so discontinued
treatment with tr; EF 3D and GLS were able to identify early on a significant reduction
in left ventricular function, even after the first cycle of EC and before the start of Tr ;
while EF 2D decreasead significantly only after the start of Tr. Neither the assessment
of systolic tissue speed at the level of annulus nor the ratio E/e’ (ratio between E wave of
transmitral flow and wave e’ of TDI) significantly change during treatment. From
baseline whether Ventricular Elastance or Ventricular-Arterial Coupling worsened
progressively during the treatment.
Conclusions: The evaluation of left ventricular function with new echocardiographic
methods with three-dimensional approach allows early identification of
cardiac-toxicity linked to CT and targeted agents, than the ventricular ejection fraction
evaluated two-dimensionally and tissue indices derived from TDI. This could allow a
prompt treatment of cardiac demage and the completion of antineoplastic therapy.
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